To Get Full Access :

Romvimza

Romvimza is a tablet for adults with tenosynovial giant cell tumor when surgery might worsen joint function. It blocks CSF-1R to shrink tumors and ease symptoms.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

  • Molecule Name :

    Vimseltinib
  • Innovator :

    DECIPHERA PHARMACEUTICALS LLC
  • Approval Date :

    14-Feb-25
  • NCE-1 Date :

    14-Feb-29
  • NCE Date :

    14-Feb-30
  • Dosage Form :

    Oral Capsule
  • Strength :

    14MG, 20MG and 30MG
  • Therapeutic Category :

    Anticancer
  • Revenue ($M) :

    NA

Year-wise Projected Sales ($M) :

  • 2025 :

    38
  • 2026 :

    73
  • 2027 :

    105
  • 2028 :

    134
  • 2029 :

    160
  • 2030 :

    185
  • 2031 :

    209
Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

For full access Sign-up / Sign-in using below Methods:

By continuing, you agree to our Terms & Conditions and Privacy Policy. You can review them anytime.

Are you sure want to logout from NCE Grid?